DESTINY-PANTUMOUR04

Launched by ASTRAZENECA · Aug 13, 2025

Keywords

ClinConnect Summary

This clinical trial, called DESTINY-PANTUMOUR04, is studying a medicine called T-DXd to see how well it works in people with certain advanced cancers that have a specific marker called HER2-positive. These cancers can include many types, like bladder, ovarian, pancreatic, or lung cancers, among others. The trial is for patients whose cancer has spread or cannot be removed by surgery, who have already tried other treatments that didn’t work well enough, and who don’t have other good treatment options available.

To join the study, participants need to be adults with HER2-positive tumors confirmed by testing, and their doctor must have decided that T-DXd is the right treatment for them. People who have had certain types of cancer, like breast or colon cancer, or who have already taken T-DXd before, will not be eligible. Those who join will receive treatment with T-DXd and will be monitored in a real-world setting to understand how effective and safe the medicine is for patients like them. The trial is not yet recruiting, and it welcomes adults of any gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged ≥18 years
• • 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);
• • 3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;
• • 4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;
• • 5. Patients who are willing and able to provide a signed and dated informed consent.
• Exclusion Criteria:
• • 1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;
• • 2. Prior T-DXd therapy;
• • 3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.
• • 4. Patient is participating in a clinical trial at time of enrolment